Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 5,500 shares, a drop of 68.8% from the October 15th total of 17,600 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 28,400 shares, the short-interest ratio is currently 0.2 days.

Synaptogenix Stock Down 6.7 %

Shares of Synaptogenix stock traded down $0.20 during trading on Wednesday, reaching $2.80. 26,770 shares of the company were exchanged, compared to its average volume of 37,892. The business has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.83. Synaptogenix has a twelve month low of $2.72 and a twelve month high of $8.78.

Synaptogenix (NASDAQ:SNPX) last posted its earnings results on Wednesday, August 14th. The company reported ($1.18) earnings per share (EPS) for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.